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mortality. This study develops and validates a specific prognostic
score for ACLF patients.
Methods: Data from 1349 patients included in the CANONIC
study were used. First, a simplified organ function scoring system
(CLIF Consortium Organ Failure score, CLIF-C OFs) was developed
to diagnose ACLF using data from all patients. Subsequently, in
275 patients with ACLF, CLIF-C OFs and two other independent
predictors of mortality (age and white blood cell count) were
combined to develop a specific prognostic score for ACLF (CLIFJournal of Hepatology 20
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assessment; SpO2, pulse oximetric saturation.Consortium ACLF score [CLIF-C ACLFs]). A concordance index
(C-index) was used to compare the discrimination abilities of
CLIF-C ACLF, MELD, MELD-sodium (MELD-Na), and Child-Pugh
(CPs) scores. The CLIF-C ACLFs was validated in an external cohort
and assessed for sequential use.
Results: The CLIF-C ACLFs showed a significantly higher
predictive accuracy than MELDs, MELD-Nas, and CPs, reducing
(19–28%) the corresponding prediction error rates at all main
time points after ACLF diagnosis (28, 90, 180, and 365 days) in
both the CANONIC and the external validation cohort. CLIF-C
ACLFs computed at 48 h, 3–7 days, and 8–15 days after ACLF
diagnosis predicted the 28-day mortality significantly better than
at diagnosis.
Conclusions: The CLIF-C ACLFs at ACLF diagnosis is superior to
the MELDs and MELD-Nas in predicting mortality. The CLIF-C
ACLFs is a clinically relevant, validated scoring system that can
be used sequentially to stratify the risk of mortality in ACLF
patients.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Acute-on-chronic liver failure (ACLF) is a syndrome characterised
by acute decompensation of cirrhosis, organ failure(s) and high
short-term mortality [1], which was recently defined in the
CANONIC study [2]. This was a large prospective observational
investigation carried out in 29 European university hospitals. It
included 1349 consecutive patients admitted with acute14 vol. 61 j 1038–1047
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decompensation of cirrhosis (ascites, bacterial infection,
gastro-intestinal haemorrhage, and hepatic encephalopathy)
and followed-up for one year. The CANONIC study was organised
in the setting of the European Association for the Study of the
Liver – Chronic Liver Failure Consortium (EASL CLIF-C).
The results of the CANONIC study showed that ACLF occurs
most frequently in relatively young individuals, affects approxi-
mately 30% of hospitalised cirrhotic patients, may develop in
patients without previous decompensation, is associated with a
28-day mortality rate of 33% (51% at 90 days) and is distinct from
‘mere’ decompensation of cirrhosis. ACLF is the most frequent
indication for admission to the intensive care unit (ICU) [3]. In
the US, about 200,000 patients with cirrhosis are hospitalised
each year of which about 26,000 patients require ICU care
[1,3,4]. An average ICU admission costs about $116,200 and costs
for the health care system are $3 billion for cirrhotic patients
requiring intensive care [3].
The diagnostic criteria for ACLF in the CANONIC study were
based on the Chronic Liver Failure-SOFA score (CLIF-SOFAs), an
adaptation for cirrhotic patients of the sepsis organ failure assess-
ment score (SOFAs) widely used in the ICU [4]. The CLIF-SOFAs,
however, is complex (based on 6 subscores, each with a 5-point
range, assessing liver, kidney, brain, coagulation, respiration,
and circulation), is based on consensus and expert opinion rather
than data, and does not significantly improve the prediction accu-
racy of the model for end-stage liver disease (MELD) and MELD-
sodium (MELD-Na) scores [5–6].
The current study was aimed to simplify the original
CLIF-SOFAs and develop a new score for ACLF patients (CLIF
Consortium ACLF score, CLIF-C ACLFs) with a higher prognostic
accuracy than the CLIF-SOFA, MELD, MELD-Na, and the
Child-Pugh (CP) scores [7] for patients with ACLF. The study
therefore had four main objectives. First, to develop a simpler
and validated organ failure score (CLIF Consortium Organ Func-
tion score, CLIF-C OFs) for the diagnosis and grading of ACLF.
Second, to design a more accurate prognostic score for ACLF
patients (CLIF-C ACLFs), using the CLIF-C OFs and other prog-
nostic clinical and biochemical data. Third, to compare the
prognostic accuracy of the CLIF-C ACLFs to that of MELDs,
MELD-Nas, and CPs. Fourth, to validate the prognostic accuracy
of the CLIF-C ACLFs in an external prospective cohort of con-
secutive patients hospitalized in a single ICU and assess the
score for sequential use.
The CANONIC study database was used as a derivation set for
several reasons: first, it includes a large series of patients with
acute decompensated cirrhosis and also with ACLF. Second,
CANONIC patients were closely and prospectively followed-up
for up to 1-year. Third, the population with ACLF included
patients developing the syndrome either at study inclusion or
during the hospitalization period. Finally, as patients were
recruited from 29 centres in Europe, the CANONIC data are repre-
sentative of the European patient population.Patient and methods
Study populations
The study was performed in patients from three different populations. Both the
derivation and the validation datasets came from studies approved by Ethical
Review Boards of all study sites.Journal of Hepatology 20141. The CLIF-C OFs was developed using the baseline (i.e., enrolment) data of the
whole CANONIC study population, which included 1349 patients (out of 2149
screened) admitted to 29-European hospitals within a period of 6 months for
the treatment of decompensated cirrhosis. These patients were prospectively
followed-up for one year [2]. In most patients (52%) the aetiology of cirrhosis
was alcoholic, in 19.5% it was associated with chronic hepatitis C virus infec-
tion, and in 9.6% it was due to both alcohol and hepatitis C. In the remaining
18.9%, cirrhosis was due to other causes. 345 patients (26.8%) had no history
of previous decompensation. Causes of hospitalization at study enrolment
were ascites (66.8%), hepatic encephalopathy (34.3%), bacterial infections
(24.2%), and/or gastro-intestinal haemorrhage (16.4%). 196 patients (14.6%)
were admitted to the ICU. The MELDs at enrolment in the whole series was
18.8 (SD: 7.5), and CPs was 9.7 (SD: 2.1).
2. The CLIF-C ACLFs was developed using data from 275 CANONIC patients with
ACLF at enrolment, or those who developed ACLF within 28-days post-
enrolment. Diagnostic criteria for organ failures in the CANONIC study are
described in Supplementary Table 1. The diagnosis of ACLF was based on
the presence of at least renal failure or any other single organ failure if
associated with renal dysfunction (serum creatinine 1.5–1.9 mg/dl) and/or
grade I–II hepatic encephalopathy (ACLF-1). Patients with two organ failures
were graded as ACLF-2 and those with three or more organ failures as ACLF-3.
At study enrolment, 70.1% of these patients were admitted to the ICU.
3. The external validation of the CLIF-C ACLFs was carried out using data from
225 ACLF patients consecutively admitted to the ICU at the Paul Brousse
hospital, Villejuif, France [8]. Despite differences in the proportion of patients
admitted to the ICU, this series of patients was selected as the validation set
for the following reasons: (1) it was a prospective cohort; (2) all patients had
the data needed for ACLF diagnosis and score calculations; (3) patients were
followed-up for 90-days. Table 1 shows the clinical characteristics of patients
included in the derivation and validation sets.
Study outcomes
The main study outcomes included all-cause mortality at 28, 90, 180, and
365 days after enrolment. All CANONIC patients were closely followed-up during
the first 28 days. Subsequently, data on vital signs, causes of death and liver
transplantation were obtained 3, 6, and 12 months after enrolment. The same
information was collected for all ACLF patients in the validation cohort, who were
followed-up for 3 months only. In both derivation and validation sets, there were
no losses due to follow-up. At 90 days, 38/275 (13.8%) ACLF patients underwent
liver transplantation in the CANONIC dataset and 22/225 (9.8%) in the validation
cohort. One year after study enrolment, 53/275 (20%) CANONIC patients with
ACLF had been transplanted.
All the data required to compute CLIF-C ACLFs (as well as those used to com-
pute MELDs, MELD-Nas, and CPs) were measured at the time of ACLF diagnosis
(either at enrolment or within the 28-day post-enrolment follow-up). Patients’
parameters were collected based on standard lab measurements performed at
study enrolment and at day 2, 3–7, 8–14, 15–21, and 22–28 during the hospital-
ization. A central laboratory was not used for sample analyses. However, to assure
the comparability of lab results, site labs were requested to use the same units
and normal ranges; extensive remote monitoring and quality control were carried
out during and after study termination.
Statistical methods
Variables used for the CLIF-C OFs and CLIF-C ACLFs were measured at enrolment
and at ACLF diagnosis. The original CLIF-SOFAs included 6 subscores – one for
each organ/system – each of them ranging from 0 to 4 (Supplementary Table 1).
The 5 categories included in CLIF-SOFAs subscores and the corresponding cut-off
values were derived from a consensus [2]. In the current study we assessed
whether the cut-offs could be modified and/or if the number of the original cat-
egories of each subscore could be reduced maintaining the predictive ability of
the aggregated score.
In univariate statistical comparisons, the v2 test was used for categorical
variables, Student’s t test and Mann-Whitney test for continuous variables.
McNemar’s test and paired t test were used to compare repeated measurements
of categorical and continuous variables, respectively. Proportional hazards mod-
els considering liver transplantation as a competing risk (PH-CR) were used to
identify additional independent factors of mortality not included in the CLIF-C
OFs system. Transplanted patients were considered as censored and the survival
function was adjusted for the risk of liver transplantation at each study time point
[9,10].vol. 61 j 1038–1047 1039
Table 1. Baseline characteristics and outcome of patients with an acute-on-chronic liver failure (ACLF) episode included in the CANONIC study and in the external
validation datasets.






Age (yr) 54.5 ± 12.1 55.1 ± 11.1 0.567
Male sex 176 (64.0) 171 (76.0) 0.005
Presence of ascites 218 (80.2) 206 (93.2) <0.001
Etiology of cirrhosis
Alcohol 147 (54.7) 158 (70.2) <0.001
HCV 40 (14.9) 24 (10.7) 0.218
Alcohol + HCV 29  (10.8) 14 (6.2) 0.100
Site of hospitalization at study enrolment
Intensive care unit 192 (70.1) 225 (100) <0.001
Data used to compute CLIF-OF score
Serum bilirubin (mg/dl) 12.3 ± 11.5 13.3 ± 12.7 0.360
Serum creatinine (mg/dl) 2.0 ± 1.3 2.0 ± 1.5 0.721
HE grade I-II 102 (37.5) 111 (49.3) <0.001
HE grade III-IV 60 (22.1) 62 (27.6)
INR 2.2 ± 1.0 3.8 ± 2.8 <0.001
Serum sodium (mEq/L) 135 ± 7 134 ± 8 0.137
White-cell count (x109 cells/L) 10.0 ± 6.3 7.8 ± 4.3 <0.001









39 (14.2) 86 (38.2)
Acute-on-chronic liver failure (ACLF) grade and scores
ACLF grade 1 121 (44.0) 51 (22.6)
<0.001ACLF grade 2 110 (40.0) 71 (31.6)
ACLF grade 3 44 (16.0) 103 (45.8)
Child-Pugh score 11.1 ± 2.0 11.4 ± 1.9 0.104
MELD score 28 ± 8 31 ± 8 <0.001
MELD-Na score 30 ± 7 33 ± 7 <0.001
Mortality rates
28-Day mortality 93 (33.8) 117 (52.0) <0.001
90-Day mortality 133 (48.4) 141 (62.7) 0.002
6-Month mortality 143 (52.0)
1-Year mortality 159 (57.8)
Data are numbers of patients (%) or mean ± SD.
HE, hepatic encephalopathy; FiO2, fraction of inspired oxygen; PaO2, partial pressure of arterial oxygen; SpO2, pulse oximetric saturation.
Research ArticleBaseline factors, not accounted for in the CLIF-C OFs, and significantly
(p <0.05) associated with mortality at 28, 90, 180, and 365 days, were selected
for the final models. PH-CR models including the CLIF-C OFs and all the other
selected factors were fitted applying a forward step-wise selection method with
p-in = 0.05 and p-out = 0.1. The factors that were independently associated with
mortality at the main time points were included in the CLIF-C ACLFs. The coeffi-
cients estimated for each factor in the 28-day model, which provided the best
predictive ability, were used as relative weights to compute the CLIF-C ACLFs.
The calibration of the CLIF-C ACLFs was assessed by comparing the actual
observed risk and the average probability of dying at different time points pre-
dicted by the score. The Hosmer-Lemeshow test was used to assess the corre-
sponding goodness-of-fit. The Harrell’s concordance index (C-index) was used
to assess the score’s discrimination ability [11,12]. Since the CLIF-C ACLFs was
derived based on a PH-CR model, C-index values and the corresponding 95%
confidence intervals (CIs) were estimated for each main study time point, treating
the transplanted patients as censored at the end of the period, assuming that1040 Journal of Hepatology 2014none of them would die before [9]. Statistical comparisons of the C-index
between the CLIF-C ACLFs, CLIF-SOFAs, CLIF-C OFs, MELDs, MELD-Nas, and CPs
were carried out for the main study time points using the integrated discriminat-
ing improvement (IDI) statistic [13].
For external validation [14], the CLIF-C ACLFs was computed with the valida-
tion data, and score performance was assessed and compared to that of the
MELDs, MELD-Nas, and CPs by means of the same methods applied to the CANO-
NIC data. To corroborate the results observed in the derivation and validation
sets, a confirmatory analysis was carried out by estimating the Area Under the
ROC curve (AUROC) of the CLIF-C ACLFs for predicting 28-day and 90-day mortal-
ity. This also allowed us to identify the best score cut-points, which maximized
the sensitivity, specificity and predictive values.
The prognostic ability of the CLIF-C ACLFs, and MELDs for sequential use was
assessed using a subset of CANONIC patients with ACLF and data available at the
time of diagnosis and at 48 h, 3–7 days, and at 8–15 days after diagnosis. Post-
diagnosis C-indexes were compared with the baseline by means of paired t tests.vol. 61 j 1038–1047
Table 2. The CLIF-organ failure score system.
Organ/system Subscore = 1 Subscore = 2 Subscore = 3
Liver Bilirubin <6 mg/dl Bilirubin ≥6 mg/dl 
and <12 mg/dl
Bilirubin ≥12 mg/dl




Brain (West-Haven grade for HE*) Grade 0 Grade 1-2 Grade 3-4**
Coagulation INR <2.0 INR ≥2.0 and <2.5 INR ≥2.5














The shaded area describes criteria for diagnosing organ failures.
⁄HE, hepatic encephalopathy; FiO2, fraction of inspired oxygen; PaO2, partial pressure of arterial oxygen; SpO2, pulse oximetric saturation.
⁄⁄Patients submitted to Mechanical Ventilation (MV) due to HE and not due to a respiratory failure were considered as presenting a cerebral failure (cerebral subscore = 3).
#Other patients enroled in the study with MV were considered as presenting a respiratory failure (respiratory subscore = 3).
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ACLF study populations
Table 1 shows the two ACLF study populations. ACLF patients in
the external validation cohort were more frequently male and
alcoholic, had more severe ACLF and higher rates of ascites, hepa-
tic encephalopathy, respiratory and circulatory failure than ACLF
patients in the CANONIC cohort. Consequently, the MELDs and
MELD-Nas and the 28-day and 90-day mortality rates were
higher in the validation cohort.
Development of the CLIF-C OFs
For each organ system, two new cut-points were chosen to dis-
tinguish three clinical severity categories that were directly cor-
related with the risk of dying at 28-days. The new cut-off
values maximised the ability of the aggregated score (ranging 6
to 18) to predict 28-day mortality. Derivations of the resulting
organ system subscores are reported in Table 2. The performance
of the CLIF-C OFs (C-index: 0.72) in predicting 28-day mortality
was identical to that of the original CLIF-SOFAs (C-index esti-
mate: 0.72 [p = 0.856]) and slightly but significantly superior to
those of MELDs, MELD-Nas and CPs (C-index: 0.69 [p = 0.015],
0.68 [p = 0.019] and 0.67 [p = 0.014] respectively).
Development of the CLIF-C ACLFs
Baseline factors, not included in the CLIF-C OFs and significantly
associated with short- and long-term mortality, were alcoholic
aetiology of cirrhosis, ascites (as clinically diagnosed), AST, serum
sodium, serum potassium and white blood cell (WBC) count
(Supplementary Table 2). Age was included in all models as a
well-known potential confounder. Together with the CLIF-C
OFs, age and log-transformed white blood cell count were
selected as the best predictors. The CLIF-C ACLFs was computed
by applying model coefficients and was trimmed between 0
and 100, since upper values did not modify the expected
probabilities of dying by more than 1%:
CLIF-C ACLFs ¼ 10 ½0:33 CLIF-OFsþ 0:04 Ageþ 0:63
 lnðWBC countÞ  2Journal of Hepatology 2014The probability of death at time ‘‘t’’ can be estimated by the
equation:
P ¼ 1 e½CIðtÞexpðbðtÞCLIF-C ACLFsÞ
CI(t) and b(t) are the cumulated baseline hazard and the score
coefficient estimated by the model fitted for time t. At the main
time points they are: CI(28) = 0.0022, b(28) = 0.0995; CI(90) =
0.0079, b(90) = 0.0869; CI(180) = 0.0115, b(180) = 0.0824;
CI(365) = 0.0231, b(365) = 0.0731.
An online application to estimate the predicted death rate at
time t based on the CLIF-C ACLFs will be available at the CLIF
Consortium website: http://www.clifconsortium.com/. A freely
downloadable application is also available (CLIFC ACLFs).
Calibration of the CLIF-C ACLFs
Fig. 1 shows the observed and predicted probability of dying at
28 days by the CLIF-C ACLFs quintiles in the CANONIC and in the
validation datasets. In the derivation set, predicted and observed
probabilities of death were similar across the quintiles of CLIF-C
ACLFs (Hosmer-Lemeshow v2 = 7.9, p = 0.44) and at the four
study time points: 28-days: overall predicted 0.28 vs. overall
observed 0.34; 90-days: 0.46 vs. 0.48; 6-month: 0.51 vs. 0.52;
1-year: 0.59 vs. 0.58. The calibration of the CLIF-C ACLFs was also
assessed for the validation dataset with similar results: observed
and estimated probabilities of death were comparable at the main
study time points (28-days: predicted 0.45 vs. observed 0.52; 90-
days: 0.64 vs. 0.63) and the Hosmer-Lemeshow test for the 28-day
mortality did not show a significant lack of fit (v2 = 4.0, p = 0.26).
Discrimination ability of the CLIF-C ACLFs. Comparison with the
CLIF-C OFs, CLIF-SOFAs, MELDs, MELD-Nas and the CPs
The C-index of the CLIF-C ACLFs for 28-day, 90-day, 6-month and
1-year mortality (0.76, 0.73, 0.72, and 0.71) was significantly bet-
ter than those corresponding to the CLIF-C OFs (0.72 [p <0.001],
0.68 [p <0.001], 0.67 [p <0.001], and 0.66 [p = 0.003]), and CLIF-
SOFAs (0.72 [p <0.001], 0.68 [p <0.001], 0.67 [p <0.001], and
0.66 [p = 0.002]).
The CLIF-C ACLFs showed a significantly higher predictive
discrimination than the MELDs, MELD-Nas, and CPs at 28-days
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Fig. 1. Observed (light blue) vs. predicted (dark blue) 28-day mortality rates:
according to the approximate quintiles of the CLIF-C ACLF score in the ACLF
patients included in the derivation set (left side) and validation set (right
side). The mortality probabilities predicted using the CLIF-C ACLFs score were
similar to those observed in both sets of patients, thus indicating a good


























































































Fig. 2. Percent reduction in prediction error rates of the CLIF-C ACLF score as
compared to the Child-Pugh, MELD, and MELD-Na scores at the main study
time points. The prediction error rates observed using CLIF-C ACLFs were 19% to
28% lower than those observed for MELDs, MELD-Nas or CPs in the derivation set
and 25% to 28% lower in the validation cohort.
Research Articleabsolute improvements of about 7–8 points in the C-index
values with respect to the MELDs, MELD-Nas and CPs were
consistently significant at all time points. Fig. 2 shows the
corresponding percent improvement obtained with the
CLIF-C ACLFs in prediction error rate with respect to the other
scores (computed as percent reduction in discordance rate of
the CLIF-C ACLFs vs. the reference (REF) score, i.e.,
100  [C-indexCLIF-C ACLFs  C-indexREF]/[1  C-indexREF]). The
CLIF-C ACLFs consistently improved the prediction error rates
observed for the MELDs, MELD-Nas, and CPs by 19%–28% at
all study time points.
Validation of the CLIF-C ACLFs
The comparative C-index estimates for the validation data cohort






CANONIC PATIENTS (N = 275)
28-day mortality 0.760 (0.715-0.805) 0.
p value vs. CLIF-C* <0
90-day mortality 0.732 (0.691-0.773) 0.
p value vs. CLIF-C* <0
180-day mortality 0.723 (0.683-0.763) 0.
p value vs. CLIF-C* <0
365-day mortality 0.707 (0.668-0.746) 0.
p value vs. CLIF-C* <0
Validation database (N = 225)
28-day mortality 0.744 (0·702-0.787) 0.
p value vs. CLIF-C* <0
90-day mortality 0.736 (0.696-0.776) 0.
p value vs. CLIF-C* <0
⁄p values from the Integrated Discriminating Improvement (IDI) statistics test.
1042 Journal of Hepatology 2014each main time point was significantly better than for the MELDs,
MELD-Nas and CPs (Supplementary Fig. 1). The CLIF-C ACLFs
improved the 28-day and 90-day mortality predictions by about
25% to 28% as compared to the MELDs, MELD-Nas, and CPs
(Fig. 2).
Figs. 3 and 4 show the results of the confirmatory analysis of
the predictive ability of the CLIF-C ACLF score for the 28-day and
90-day mortality in the CANONIC patients with ACLF. As com-
pared to the MELDs, MELD-Nas, and CPs, the AUROCs estimated
for the CLIF-C ACLFs were significantly higher and indicated a
7% to 11% improvement in the discrimination ability, so confirm-
ing the concordance index estimates shown in Table 3. A CLIF-C







668 (0.610-0.726) 0.687 (0.635-0.738) 0.684 (0.632-0.736)
.001 <0.001 <0.001
655 (0.605-0.705) 0.659 (0.615-0.710) 0.663 (0.617-0.709)
.001 <0.001 0.001
642 (0.593-0.691) 0.652 (0.607-0.697) 0.654 (0.609-0.699)
.001 <0.001 0.001
636 (0.588-0.683) 0.638 (0.595-0.682) 0.640 (0.597-0.683)
.001 <0.001 <0.001
653 (0.603-0.704) 0.645 (0.593-0.697) 0.648 (0.597-0.700)
.001 <0.001 <0.001
647 (0.599-0.695) 0.635 (0.585-0.684) 0.637 (0.588-0.686)
.001 <0.001 <0.001


















CLIF-C ACLFs 0.79 (0.73-0.85)
MELDs 0.70 (0.62-0.77) 0.0089
MELD-Nas 0.70 (0.62-0.77) 0.0097





Fig. 3. Accuracy of the CLIF-C ACLFs as compared to that of MELDs, MELD-Nas
and CPs in predicting 28-day mortality of the CANONIC patients with ACLF.
Comparison of the area under the ROC curves (AUROCs) estimated for each score.
The CLIF-C ACLFs showed a significantly higher predictive ability in comparison


















CLIF-C ACLFs 0.76 (0.70-0.83)
MELDs 0.65 (0.58-0.72) 0.0014
MELD-Nas 0.67 (0.60-0.74) 0.0082





Fig. 4. Accuracy of the CLIF-C ACLFs as compared to that of MELDs, MELD-Nas,
and CPs in predicting 90-day mortality of the CANONIC patients with ACLF.
Comparison of the area under the ROC curves (AUROCs) estimated for each score.
The CLIF-C ACLFs showed a significantly higher predictive ability in comparison
with all the other scores. (This figure appears in colour on the web.)
JOURNAL OF HEPATOLOGY97% sensitivity, while a score of 60 or higher allowed for a 82%
positive predictive value and 94% specificity. A score cut-off of
51 maximized both the sensitivity (64%) and the specificity
(75%), but was found to have lower negative (69%) and positive
(70%) predictive values. In the validation set comparable results
were observed: a CLIF-C ACLFs of 40 or lower had a 77% negative
predictive value and 97% sensitivity, while a score of 60 or higher
showed a 91% positive predictive value and 93% specificity.
Sequential use of the CLIF-C ACLFs
Table 4 reports the C-index estimates for the CLIF-C ACLFs and
the MELDs computed at ACLF diagnosis and at 48 h, 3–7 days,
and 8–15 days after ACLF diagnosis in the 256 CANONIC studyJournal of Hepatology 2014patients with follow-up clinical and laboratory data. Both scores,
when used sequentially, improved their predictive performance.
The CLIF-C ACLFs computed at 3–7 days and 8–15 days after ACLF
diagnosis predicted 28-day and 90-day mortality significantly
better than the CLIF-C ACLFs at ACLF diagnosis. Interestingly,
the sequence of C-index estimates reflected a consistent differ-
ence of 7–8 points between the CLIF-C ACLFs and the MELDs in
the corresponding discrimination abilities.Discussion
The observation in the CANONIC study that ACLF occurs in 30% of
hospitalised cirrhotic patients, is associated with a 28-day mor-
tality rate of 32%, has well-defined diagnostic criteria, and is
pathophysiologically related to systemic inflammation provides
the rationale for new investigations on the mechanism and
management of this syndrome [1,2,8,15,16]. Consequently, it is
necessary to develop an accurate prognostic score for ACLF
patients.
Any specific score for ACLF should have the following
characteristics. First, the score should be as simple as possible
to facilitate clinical use and be based on the function of the vital
organ-systems defining the ACLF syndrome [2]. Second, parame-
ters estimating organ failure should be easy to obtain in standard
hospitalization settings [3,8,15,16]. Third, the cut-off levels for
the definition of organ system failure should have prognostic
significance. Fourth, the score should provide computed figures,
estimating risk of mortality but also allow an easy stratification
of patients with clinical and prognostic significance. Finally, it
should clearly improve the predictive ability of the main
prognostic scores currently available (MELDs and CPs).
The first step of this study was to develop a simplified score
based on organ function (the CLIF-C OFs), using the data obtained
from all patients included in the CANONIC study [2]. As indicated
above, the main objective of this new score was to diagnose and
grade the severity of ACLF. The CLIF-C OFs, which has a 3-point
range per organ system and an aggregated score ranging from 6
to 18, is simpler than the original CLIF-SOFAs used in the CANO-
NIC study from which it derives (5 point ranges and aggregated
score range 0–24) and accomplishes all the above mentioned cri-
teria except the last one. Interestingly, the prognostic significance
of cut-off levels for the diagnosis of organ failures of the original
CLIF-SOFAs were confirmed in the CLIF-C OFs [2]. Therefore, diag-
nosis of organ failure and the stratification of ACLF proposed by
the CANONIC study are also applicable using the CLIF-C OFs. In
the CANONIC patients with ACLF, the predictive accuracy of the
CLIF-C OFs was identical to that of the CLIF-SOFA score and
slightly but significantly better than those of the MELDs,
MELD-Nas, and CPs.
The second step of the study was to develop a prognostic
score better than the CLIF-C OFs for patients with ACLF. The strat-
egy used was to analyse patients with ACLF in the CANONIC data-
base looking for independent factors associated with mortality
not included in the CLIF-OFs and to subsequently fit a final sur-
vival model with the CLIF-OFs and the selected factors. Age and
white blood cell count (a crude marker of systemic inflammation)
were found to be the best predictors. These parameters have also
been found to be independently associated with mortality in
previous studies [2,8,15–19]. Although in the CANONIC study,
white blood cell count was higher in patients with alcoholic livervol. 61 j 1038–1047 1043
Table 4. Sequential use of the CLIF-C ACLF and MELD score to predict mortality in CANONIC patients with ACLF and post-enrolment clinical and laboratory
follow-up.
28-day mortality 90-day mortality
CLIF-C ACLF score MELD score CLIF-C ACLF score MELD score
C-index
(95% CI)
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Research Articledisease and active alcoholism, the data also showed that irrespec-
tive of aetiology, higher white blood cell count was associated
with more severe grades of ACLF [2]. Through the final model
including a CLIF-C OFs with these two new variables, we were
able to obtain a new score (CLIF-C ACLFs) ranging between 0
and 100 points, which predicted the risk of mortality accurately.
The concordance index analysis in the derivation cohort
showed that the CLIF-C ACLFs was more accurate in predicting
short-term and long-term mortality than their predecessors
CLIF-SOFAs and CLIF-C OFs (data not shown) and also than
MELDs, MELD-Nas, and CPs. The differences in predictive discrim-
ination between the CLIF-C ACLFs and MELDs, MELD-Nas, and CPs
at 28 and 90-days were even more significant in the validation
cohort. The fact that these patients were more severely ill than
those in the derivation cohort probably accounts for this observa-
tion. The analysis of the prediction errors, observed with the CLIF-
C ACLFs compared with MELDs, MELD-Nas, and CPs in both the
derivation and the validation cohorts, is additional evidence of
the superiority of the CLIF-C ACLFs over the other scores in pre-
dicting mortality in ACLF patients. Using the CLIF-C ACLFs leads
to a substantial improvement (19% to 28%) in the discrimination
ability observed with MELDs, MELD-Nas, and CPs.
We also assessed whether the CLIF-C ACLF score could be useful
if applied sequentially to identify response to an intervention,
deterioration despite intervention and perhaps act as a guide to
determine whether further interventions are likely to be futile.
The data showed that the performance of the CLIF-C ACLFs
improved significantly if repeated 48 h, 3–7 d or 8–15 d after the
initial determination. These data suggest that, in clinical practice,
the CLIF-C ACLFs, like the SOFAs, which is widely used in the ICU
for non-cirrhotic patients, can be updated on a daily basis provid-
ing additional prognostic information [4]. Currently, no validated
evidence-based tools guide the decision-making. Sequential mea-
surements of the CLIF-C ACLFs may help to define potential futility.
In summary, using the CANONIC database we derived a new,
evidence-based and simpler organ-failure score (CLIF-C OFs) to
diagnose organ failures and ACLF in cirrhotic patients. The
CLIF-C OFs includes parameters most commonly used in the
management of ACLF patients and shows a prognostic accuracy
similar to its predecessor, the CLIF-SOFAs but significantly higher
than MELDs, MELD-Nas, and CPs. Combining the CLIF-C OFs with
age and white blood cell count, the CLIF-C ACLFs was obtained as
a specific prognostic score for ACLF patients and validated in an
external cohort of ACLF patients. CLIF-C ACLFs allowed a signifi-
cant improvement of the discrimination ability as compared to1044 Journal of Hepatology 2014the MELDs, MELD-Nas, and CPs, as indicated by a 19% to 28%
reduction in percent prediction errors observed in both the deri-
vation and validation datasets. The CLIF-C ACLFs also proved to be
potentially useful for sequential use after ACLF diagnosis but this
will require further validation.Financial support
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